An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects |
| |
Authors: | Wojciech Krzyzanski Juan Jose Perez-Ruixo |
| |
Affiliation: | (1) Department of Pharmaceutical Sciences, University at Buffalo, 547 Cooke Hall, Buffalo, New York 14260, USA;(2) Clinical Pharmacology, Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, Turnhoutseweg 30, Beerse, 2340, Belgium;(3) Pharmacy and Pharmaceutics Division, Department of Engineering, Faculty of Pharmacy, Miguel Hernández University, San Juan de Alicante (Alicante), Spain |
| |
Abstract: | Purpose An empirical pharmacodynamic model was developed to assess the effect of recombinant human erythropoietin (rHu-EPO) treatment on the reticulocyte production rate and lifespan distribution. Materials and Methods Single doses of rHu-EPO at levels 20, 40, 60, 90, 120, and 160 kIU were administered to healthy volunteers (n = 8 per dose level). Erythropoietin plasma concentrations as well as hematologic responses were measured up to 42 days. The hematological data were used to determine explicit relationships between reticulocyte and red blood cell counts (RBC) and the reticulocytes’ production rate and lifespan distribution. Results The parameter estimates obtained by simultaneous fitting of the model to the reticulocyte and RBC data revealed that rHu-EPO transiently increased the reticulocyte lifespan from the baseline value of 1.7 days to 3.4 days and the effect lasted for 8.3 days. The dose dependent increase in the reticulocyte production had the maximal value of 77.5 109 cells/l/day and was followed by a rebound that was less than 9% of the baseline value. Both reticulocyte and RBC responses were preceded by a dose-independent lag time of 1.7 days. Conclusions The effect of rHu-EPO on the reticulocyte production rate and lifespan distribution was characterized. The results of the present study can be further utilized in building more mechanistic pharmacodynamic models of rHu-EPO stimulatory effects. |
| |
Keywords: | precursor– successor relationship pharmacodynamic model lifespan recombinant human erythropoietin NONMEM |
本文献已被 PubMed SpringerLink 等数据库收录! |
|